Vertex Pharmaceuticals - European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY, for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia : vimarsana.com

Vertex Pharmaceuticals - European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY, for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

LONDON - Vertex Pharmaceuticals Incorporated announced today that the European Commission has granted conditional marketing authorization to CASGEVY , a CRISPR/Cas9 gene-edited therapy.
CASGEVY is...

Related Keywords

Australia , Boston , Massachusetts , United States , London , City Of , United Kingdom , France , Rome , Lazio , Italy , America , Reshma Kewalramani , Franco Locatelli , Heather Nichols , European Commission , European Union , Catholic University Of The Sacred Heart , Vertex Pharmaceuticals Incorporated Nasdaq , Companies To Work , Exchange Commission , Department Of Pediatric Hematology , Pharmaceuticals Incorporated , Chief Executive Officer , Sacred Heart , Pediatric Hematology , Gesu Children , Sickle Cell Disease , Transfusion Dependent Beta Thalassemia , Conditional Marketing Authorizations , Top Employers , Private Securities Litigation Reform Act , Risk Factor , News Publishing , Markets ,